Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H10O5 |
Molecular Weight | 258.2262 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=CC=C1OC(=O)C2=CC=CC=C2O
InChI
InChIKey=WVYADZUPLLSGPU-UHFFFAOYSA-N
InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
Molecular Formula | C14H10O5 |
Molecular Weight | 258.2262 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/pro/salsalate.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23817699 |
https://www.ncbi.nlm.nih.gov/pubmed/6520777
Sources: https://www.drugs.com/pro/salsalate.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23817699 |
https://www.ncbi.nlm.nih.gov/pubmed/6520777
Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001516 Sources: Salsalate selectively inhibits prostaglandin synthesis in vivo |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | DISALCID Approved UseSalsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, and related rheumatic disorder. |
|||
Palliative | DISALCID Approved UseSalsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Variable effects of nonsteroidal antiinflammatory agents on thyroid test results. | 2003 Dec |
|
Interaction of rofecoxib and celecoxib with warfarin. | 2003 Jul 1 |
|
Salicylic acid-induced inactivation of creatine kinase in the presence of lactoperoxidase and H2O2. | 2005 Jan 15 |
|
Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells. | 2005 Jan-Feb |
|
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. | 2006 |
|
Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. | 2006 Sep |
|
siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. | 2008 Aug |
|
Salsalate improves glycemia and inflammatory parameters in obese young adults. | 2008 Feb |
|
Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes. | 2008 Jul |
|
Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. | 2008 Mar 12 |
|
Role of NFkappaB in age-related vascular endothelial dysfunction in humans. | 2009 Aug 10 |
|
The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. | 2009 Mar |
|
Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. | 2009 Oct |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats. | 2010 Dec |
|
2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts. | 2010 Jul |
|
Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults. | 2010 Jul 31 |
|
Potential role of salicylates in type 2 diabetes. | 2010 Jul-Aug |
|
A systems biology approach identifies inflammatory abnormalities between mouse strains prior to development of metabolic disease. | 2010 Nov |
|
Wet oxidation of salicylic acid solutions. | 2010 Nov 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/salsalate.html
The usual dosage is 3000 mg daily, given in divided doses as follows: 1(two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:10:16 GMT 2023
by
admin
on
Fri Dec 15 15:10:16 GMT 2023
|
Record UNII |
V9MO595C9I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02BA06
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
||
|
WHO-VATC |
QN02BA06
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
||
|
LIVERTOX |
NBK548843
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
49171
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
Salsalate
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
100000086562
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
9014
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
36108
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
209-027-4
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL154111
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
DB01399
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
2420
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
SUB10434MIG
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
5161
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
m9747
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
SALSALATE
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
DTXSID1023572
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
3267
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
V9MO595C9I
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
V9MO595C9I
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
C014182
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
552-94-3
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
1609807
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY | |||
|
C62636
Created by
admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||